Free Research Reports on ACI, SNSS, SPF and USEG Issued by the Bedford Report
January 22 2013 - 7:15AM
Marketwired
The Bedford Report has released new equity reports today. As a
leading provider of free in depth reports and timely market
updates, Bedford is an essential resource for hundreds of thousands
of investors across the country.
Arch Coal Inc. (NYSE: ACI) shares have
rallied over 10 percent in the past week, but are still down nearly
45 percent in the past year. The International Energy Agency has
recently predicted that by 2017 coal will rival oil as the world's
top energy source.
Find out more about Arch Coal including
full access to the free equity report at:
www.BedfordReport.com/ACI
Sunesis Pharmaceuticals, Inc. (NASDAQ:
SNSS) was one of the top performers in the Biotech Industry Friday
gaining 8.7 percent on over 400,000 shares traded. Credit Suisse
has recently initiated coverage on the company with a "outperform"
rating and a price target of $7.00.
Find out more about Sunesis
Pharmaceuticals including full access to the free equity
report at: www.BedfordReport.com/SNSS
Standard Pacific Corp. (NYSE: SPF) U.S.
homebuilders have been some of the strongest performers on the
market. The U.S. housing market recovery has continued in 2013 as
U.S. home prices gained 7.4 percent year-over-year in November, the
largest gain seen in 6.5 years. Shares of Standard Pacific have
nearly doubled in the past year.
Find out more about Standard Pacific
including full access to the free equity report at:
www.BedfordReport.com/SPF
U.S. Energy Corp. (NASDAQ: USEG) shares
gained 9.15 percent and hit a high of $1.84 Friday. The company saw
volume of 1.03 million shares traded, which was more than 10 times
the average daily volume. The company earlier this month announced
details of their $32.5 million 2013 capital expenditure budget.
Find out more about U.S. Energy including
full access to the free equity report at:
www.BedfordReport.com/USEG
Disclaimer: Information, opinions and analysis contained herein
are based on sources believed to be reliable, but no
representation, expressed or implied, is made as to its accuracy,
completeness or correctness. The opinions contained herein reflect
our current judgment and are subject to change without notice. We
accept no liability for any losses arising from an investor's
reliance on or use of this report. This report is for information
purposes only, and is neither a solicitation to buy nor an offer to
sell securities. Certain information included herein is
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements concerning manufacturing, marketing, growth, and
expansion. Such forward-looking information involves important
risks and uncertainties that could affect actual results and cause
them to differ materially from expectations expressed herein.
A third party, Providence Media Strategies LLC has paid Equity
News Circuit four hundred and fifty dollars for the publication of
this news release. Neither Equity News Circuit, nor the hiring
party, has a financial relationship with any company whose stock is
mentioned in this release. Neither Equity News Circuit nor the
hiring party are a registered investment advisor, and nothing in
this report is intended as a solicitation to buy or sell any
security.
Contact Information: Equity News Circuit Email Contact
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2023 to Aug 2024